Table 1.

Clinical characteristics of the non-SSAR and SSAR analysis groups

	Non-SSAR Group, N=260	SSAR Group, N=79	p-value
Female Gender†	42% (109)	47% (37)	0.44
Age at Transplant‡	56 (43 – 62)	55 (39 – 62)	0.62
Race†
Caucasian	91% (236)	91% (72)	0.92
African American	9% (22)	8% (6)	0.81
Native Disease†
Obstructive	43% (112)	43% (34)	0.99
Restrictive	34% (89)	35% (28)	0.84
Cystic	21% (54)	19% (15)	0.73
Vascular	2% (5)	3% (2)	0.74
Bilateral Transplant†	92% (239)	91% (72)	0.82
Modern Transplant Era† ¥	70% (182)	71% (56)	0.88
Pre-BOS CMVP Count‡	0 (0 – 1)	0 (0 – 1)	0.70
Pre-BOS AR Episode Count‡	2 (1 – 4)	4 (2 – 6)	<0.0001
Pre-BOS AR Score‡	4 (2 – 6)	6 (3 – 9)	0.0001
Pre-BOS LB Episode Count‡	0 (0 – 1)	0 (0 – 1)	0.053
Pre-BOS LB Score‡	0 (0 – 1)	0 (0 – 2)	0.092
Pre-BOS PFTs‡	25 (18 – 33)	26 (20 – 36)	0.24
Pre-BOS Biopsies‡	10 (7 – 14)	13 (8 – 17)	0.0054

^†Percent (Number),

^‡Median (IQ Range),

^¥Transplanted after March 2002; AR, acute rejection (A grade); CMVP, cytomegalovirus pneumonitis; LB, lymphocytic bronchiolitis (B grade); PFT, pulmonary function test.